← Leaderboards
John Marshall
Brown University
$5,052,928
Attributed
$7,451,401
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $975K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,451,401 · 8
By mechanism
R01$4,852,875 · 3
R21$1,334,455 · 3
R41$911,475 · 1
R43$352,596 · 1
Top collaborators
- Adam Chodobski5 shared
- Xiaodi Felix Chen2 shared
- Edith Mathiowitz2 shared
- Ruth M Colwill1 shared
- Elizabeth Garcia1 shared
- Keykavous Parang1 shared
- Angela L Slitt1 shared
Most similar at Brown University
Same institution · by research overlap
- Joel D Richter$33,526,627
- Edith Mathiowitz$1,551,813
- Ruth M Colwill$738,592
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPropertySignal TransductionDoseNeuronsBrain-Derived Neurotrophic FactorAffectGlutamate ReceptorNovel TherapeuticsLong-Term PotentiationLearningAttenuatedMediatingBrainCell DeathDisabilityNeuroprotectionPreventCyclic PeptidesRattusBaseDesignApoptosisHippocampus (Brain)
Grant awards (22)
A Novel BDNF Potentiator for the Treatment of Neonatal Brain Injury$214,733
R21 · FY2025 · NS · contact PI
A novel BDNF potentiator for the treatment of neonatal brain injury$268,020
R21 · FY2024 · NS · contact PI
A Novel Cyclic Peptide-Based Treatment for TBI$516,120
R01 · FY2020 · NS
Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression$452,622
R41 · FY2020 · MH · contact PI
A Novel Cyclic Peptide-Based Treatment for TBI$516,120
R01 · FY2019 · NS
Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression$458,853
R41 · FY2019 · MH · contact PI
A Novel Cyclic Peptide-Based Treatment for TBI$516,120
R01 · FY2018 · NS
A Novel Cyclic Peptide-Based Treatment for TBI$518,249
R01 · FY2017 · NS
A novel BDNF potentiator for Treating Cognitive Dysfunction in Angelman Syndrome$203,125
R21 · FY2017 · MH · contact PI
A Novel Cyclic Peptide-Based Treatment for TBI$563,465
R01 · FY2016 · NS
A novel BDNF potentiator for Treating Cognitive Dysfunction in Angelman Syndrome$243,750
R21 · FY2016 · MH · contact PI
Treatment of stroke using a novel PDZ binding peptidomimetic drug.$352,596
R43 · FY2011 · NS
Development of neuroprotective PDZ-domain inhibitors for the treatment of MS$170,259
R21 · FY2009 · NS · contact PI
Development of neuroprotective PDZ-domain inhibitors for the treatment of MS$234,568
R21 · FY2008 · NS · contact PI
Mechanism of L channel-mediated neuronal survival$309,405
R01 · FY2004 · NS
Modulation and Targeting of Kainate Receptors$230,905
R01 · FY2004 · NS
Mechanism of L channel-mediated neuronal survival$309,539
R01 · FY2003 · NS
Modulation and Targeting of Kainate Receptors$231,039
R01 · FY2003 · NS
Mechanism of L channel-mediated neuronal survival$309,669
R01 · FY2002 · NS
Modulation and Targeting of Kainate Receptors$231,169
R01 · FY2002 · NS
Mechanism of L channel-mediated neuronal survival$330,530
R01 · FY2001 · NS
Modulation and Targeting of Kainate Receptors$270,545
R01 · FY2001 · NS